We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

Bluejay Mining is dual listed on the London AIM Market (JAY) and Frankfurt Stock Exchange (S5WA) and is primarily focussed on advancing the Dundas Ilmenite project (previously known as the Pituffik Titanium Project) an advanced stage ilmenite project in Greenland into production in 2018. Dundas is the highest-grade mineral sand ilmenite project globally, and with just ~17% of the raised beach area having been assessed the true scale of this deposit is only just emerging. With a world-class quality resource already established, and signification expansion potential identified, the Board is confident that Dundas Ilmenite Project is capable of supporting an operation of considerable mine life as well as having extensive exploration potential.

Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow. Mercia Technologies PLC is quoted on AIM with the epic "MERC".

Mercia's 'Complete Capital Solution' initially nurtures businesses via its third party funds (now with circa £350.0million under management following recent mandate wins) and then over time Mercia can provide further funding to its 'Emerging Stars' by deploying direct investment follow-on capital from its own balance sheet. Since its IPO in December 2014, Mercia has invested over £46.0million directly across its portfolio of 'Emerging Stars'.